Immunoprecise (IPA) Stock News

ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company focused on TechBio and next-generation drug discovery, has scheduled its Q4 and full fiscal year 2025 earnings conference call for July 29, 2025, at 10:30 AM ET.

The company will release its financial results before the call and host a live webcast with a Q&A session. Participants can join via phone using toll-free number (800) 715-9871 or international number +1 (646) 307-1963 with Conference ID 3224490, or through the webcast link available on IPA's investor relations website.

ImmunoPrecise Antibodies (NASDAQ: IPA) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive business days from June 26 through July 10, 2025, ensuring its continued listing on the Nasdaq Capital Market.

CEO Dr. Jennifer Bath highlighted this achievement as recognition of IPA's evolution into a platform company focused on bio-native AI. The company's proprietary LENSai™ platform, powered by HYFT® technology, is transforming therapeutic discovery by integrating various biological data types and enabling rapid, precision-guided development. The platform has demonstrated success in predicting therapeutic interactions for novel targets, achieving near-crystallography precision without prior training data.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered biotherapeutics company, has appointed Jon Lieber to its Board of Directors. Lieber, currently CFO at Rallybio, brings over 30 years of financial and strategic leadership in biotechnology and life sciences.

Lieber's expertise spans capital markets, investor relations, and corporate development. His experience includes CFO roles at companies like Applied Genetic Technologies Corporation (AGTC) and senior positions at Danforth Advisors, Histogenics, and Repligen. He currently serves on the Board of Directors of Salarius Pharmaceuticals and will contribute to IPA's commercialization and strategic growth initiatives, particularly in expanding their LENSai™ and HYFT® platforms.

ImmunoPrecise Antibodies (NASDAQ: IPA) has validated its AI-powered epitope mapping platform, LENSai, demonstrating its ability to accurately predict antibody binding sites on completely new, unseen therapeutic targets. The platform successfully mapped 17 previously unseen antibody-protein complexes with accuracy levels comparable to its performance on training data.

Powered by IPA's patented HYFT® technology, LENSai can predict binding sites in hours using only digital sequences, significantly reducing the time and cost compared to traditional lab-based methods that take months. The platform achieved consistent AUC (Area Under the Curve) scores across both familiar and new molecular complexes, proving its ability to generalize across diverse biological structures.

ImmunoPrecise (NASDAQ: IPA) has achieved a significant milestone in developing a universal dengue vaccine using its LENSai™ Platform and HYFT® Technology. The company has validated that their newly discovered vaccine target is conserved across all four dengue virus types, demonstrating safety, immune activation, and structural stability.

The breakthrough involves a unique target site that triggers both B-cell and T-cell responses while maintaining strong predicted binding to multiple human immune system markers. Key technical findings include complete immune response testing, comprehensive safety verification against human proteins, and confirmation of structural stability. The balanced immune response profile suggests reduced risk of dangerous immune overreactions or antibody-dependent enhancement (ADE).

This validation follows the company's June 5th announcement and strengthens the candidate's translational potential as it moves toward preclinical evaluation.

ImmunoPrecise Antibodies (NASDAQ: IPA) has achieved a significant breakthrough in AI-driven drug discovery, with their AI-designed GLP-1 receptor agonist peptides showing superior or comparable performance to Semaglutide in receptor activation studies. The research, validated by independent third-party testing, demonstrates the effectiveness of IPA's LENSai platform and HYFT technology in designing peptide sequences. Two lead candidates outperformed or matched Semaglutide in controlled assays. The company is pursuing both injectable delivery studies and non-invasive delivery strategies for these candidates. This success validates IPA's AI-driven approach, which can be applied to other therapeutic targets across various disease areas. The technology has already shown success in vaccine development, particularly with dengue virus candidates.

ImmunoPrecise Antibodies (NASDAQ:IPA) has achieved a significant breakthrough in dengue vaccine development using its AI-driven LENSai platform powered by HYFT technology. The company has discovered a conserved epitope present across all four dengue virus serotypes, potentially enabling the development of a universal dengue vaccine. This discovery was made entirely through in silico methods, using over 20 million proprietary Structural HYFTs (S-HYFTs) to validate the findings. The platform's success demonstrates its ability to identify viral signatures that remain constant despite mutations, marking a significant advancement in computational vaccinology. IPA plans to extend this AI-driven vaccine design platform to other diseases including HIV, Norovirus, RSV, and potentially certain types of cancer.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutics company, has announced its engagement with CORE IR, a strategic investor and public relations firm. The partnership aims to enhance IPA's investor relations and communications initiatives. CORE IR will provide comprehensive services including strategic messaging, investor outreach, and communication program support. Dr. Jennifer Bath, CEO of IPA, emphasized this collaboration as a crucial step in improving communication with the investment community and increasing market visibility as the company executes its growth strategy. Scott Gordon, Co-Founder and President of CORE IR, expressed enthusiasm about working with IPA, recognizing the company's position as a pioneer in antibody discovery and development.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutics company, announced that CEO Dr. Jennifer Bath will present at Maxim Group's 2025 Virtual Tech Conference on Tuesday, June 3rd at 11:00 AM EDT. The conference, running from June 3rd to 5th, will focus on technological disruption across various industries, with particular emphasis on Quantum Computing and AI applications.

The virtual event, hosted on the M-Vest Platform, will feature discussions between Maxim Senior Analysts and company executives about how emerging growth companies are leveraging advanced technologies for future positioning. The conference will explore innovation impacts across healthcare, drones, consumer IoT, business solutions, and gaming & entertainment sectors.